Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0019 | 0.1572 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0047 | 0.9078 | 1 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0047 | 0.9078 | 1 |
Brugia malayi | hypothetical protein | 0.0035 | 0.595 | 0.5832 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0047 | 0.9078 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.595 | 0.5832 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.595 | 0.5832 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0019 | 0.1572 | 0.5 |
Brugia malayi | metabotropic glutamate receptor type 2 | 0.002 | 0.1849 | 0.0369 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.1572 | 0.1732 |
Schistosoma mansoni | hypothetical protein | 0.0035 | 0.595 | 0.5832 |
Echinococcus granulosus | metabotropic glutamate receptor 2 | 0.0034 | 0.5688 | 0.4884 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0041 | 0.7467 | 0.7854 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0034 | 0.5688 | 0.5484 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.1572 | 0.1732 |
Loa Loa (eye worm) | CMGC/GSK protein kinase | 0.0047 | 0.9078 | 0.8996 |
Loa Loa (eye worm) | hypothetical protein | 0.005 | 1 | 1 |
Giardia lamblia | Kinase, CMGC GSK | 0.0047 | 0.9078 | 1 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0046 | 0.8969 | 0.9855 |
Echinococcus multilocularis | glycogen synthase kinase 3 beta | 0.0047 | 0.9078 | 0.8906 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 0.1572 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1572 | 0.1732 |
Loa Loa (eye worm) | CMGC/GSK protein kinase | 0.0047 | 0.9078 | 0.8996 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0035 | 0.595 | 0.5194 |
Echinococcus multilocularis | protein kinase shaggy | 0.0047 | 0.9078 | 0.8906 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1572 | 0.1732 |
Echinococcus granulosus | protein kinase shaggy | 0.0047 | 0.9078 | 0.8906 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1572 | 0.1732 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1572 | 0.1732 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.595 | 0.5832 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 0.1572 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0019 | 0.1572 | 0.1732 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.595 | 0.5832 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1572 | 0.1732 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0019 | 0.1572 | 0.0821 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.1572 | 0.1732 |
Schistosoma mansoni | glycogen synthase kinase 3-related (gsk3) (cmgc group III) | 0.0047 | 0.9078 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.1572 | 0.0821 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0037 | 0.6437 | 0.6481 |
Plasmodium falciparum | glycogen synthase kinase 3 | 0.0047 | 0.9078 | 0.5 |
Echinococcus granulosus | glycogen synthase kinase 3 beta | 0.0047 | 0.9078 | 0.8906 |
Giardia lamblia | Kinase, CMGC GSK | 0.0047 | 0.9078 | 1 |
Loa Loa (eye worm) | glutamate receptor | 0.0041 | 0.7467 | 0.7241 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0047 | 0.9078 | 1 |
Trypanosoma brucei | protein kinase, putative | 0.0047 | 0.9078 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0035 | 0.595 | 0.5194 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1572 | 0.1732 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1572 | 0.1732 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1572 | 0.1732 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0019 | 0.1572 | 0.1732 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.005 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1572 | 0.1732 |
Plasmodium vivax | glycogen synthase kinase 3, putative | 0.0047 | 0.9078 | 0.5 |
Brugia malayi | intracellular kinase | 0.0047 | 0.9078 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.0047 | 0.9078 | 1 |
Toxoplasma gondii | cell-cycle-associated protein kinase GSK, putative | 0.0047 | 0.9078 | 0.5 |
Leishmania major | glycogen synthase kinase, putative;with=GeneDB:LinJ18_V3.0270 | 0.0047 | 0.9078 | 1 |
Echinococcus multilocularis | metabotropic glutamate receptor 2 | 0.0034 | 0.5688 | 0.4884 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.002 | 0.1849 | 0.0369 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1572 | 0.1732 |
Onchocerca volvulus | 0.0047 | 0.9078 | 0.5 | |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0035 | 0.595 | 0.5832 |
Trypanosoma cruzi | glycogen synthase kinase 3, putative | 0.0047 | 0.9078 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 4.4 uM | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production incubated for 1 hr prior to LPS-challenge measured after 20 hrs by Griess method | ChEMBL. | 22934671 |
IC50 (functional) | > 200 uM | Antiinflammatory activity in Swiss albino mouse 3T3 cells assessed as inhibition of calcium ionophore A23187-induced PGE2 synthesis incubated for 3 hrs prior to calcium ionophore A23187-challenge measured after 15 mins by enzyme immunoassay | ChEMBL. | 22934671 |
MIC (functional) | Antibacterial activity against Escherichia coli ATCC 25922 after overnight incubation by broth microdilution method | ChEMBL. | 22934671 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Mus musculus | ChEMBL23 | 22934671 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.